Carregant...
Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells
BACKGROUND: Tamoxifen (TAM) is the eminent first-line drug for endocrine therapy of hormone receptor positive premenopausal breast cancer and reduces the risk of recurrence by ∼50%. However, many patients developed TAM resistance and their diseases recurred. Our previous study on transcriptome profi...
Guardat en:
| Publicat a: | Technol Cancer Res Treat |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7989118/ https://ncbi.nlm.nih.gov/pubmed/33745390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/15330338211004916 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|